Kintor Pharmaceutical Announces Record Sales Growth and Strategic Use of Cash Flow for Core Pipeline Development

Key Highlights for Investors

• Sales Revenue Surpasses Previous Year: As of April 20, 2026, Kintor Pharmaceutical Limited has exceeded its total sales revenue for the entire year of 2025, reaching approximately RMB34 million compared to RMB32.68 million last year. The company is targeting to surpass RMB150 million in sales for the full year 2026.
• Explosive B2C E-commerce Growth:
  • Domestic B2C Segment: Sales in the first quarter of 2026 increased by 25 times year-on-year. Notably, the company’s in-house live-streaming sales initiative, launched five months ago, has driven significant momentum, producing an average daily sales figure of nearly RMB100,000 this month, with a single-day GMV record reaching RMB400,000.
  • Overseas B2C Segment: Sales revenue more than doubled, with a 150% increase in the first quarter of 2026 versus the same period in 2025.
• B2B Raw Material Sales Surge: The B2B segment generated RMB3.44 million in sales in Q1 2026, up from zero in the same period last year, and already surpassing the full-year 2025 figure.
• Strategic Use of Cash Flow: The company plans to allocate the cash flow generated from its cosmetic and raw material businesses to accelerate the development and commercialization of its core pipeline assets—KX-826, GT20029, and other pipeline products.
• Commitment to Core Business: Kintor will continue to adhere to its established strategic policies for its listing business, ensuring focus on its primary pipeline and commercial opportunities.

Potential Price-Sensitive Information

• Strong Sales Outperformance: Kintor’s sales revenue has already outstripped the previous year’s total by April, with a robust growth trajectory that could significantly improve financial performance and potentially drive share price appreciation.
• New Revenue Streams: The emergence of B2B raw material sales and the rapid expansion of live-streaming and e-commerce channels highlight new revenue sources and successful diversification efforts.
• Capital Allocation: Management’s plan to reinvest e-commerce and raw material profits into flagship drug development (notably KX-826 and GT20029) could accelerate the path to commercialization and enhance long-term shareholder value.

Details for Shareholders

Kintor Pharmaceutical Limited (Stock code: 9939) has issued a voluntary business update indicating robust growth across its B2C and B2B sales channels since the start of 2026. As of April 20, cumulative realized sales revenue for the year has reached approximately RMB34 million, already exceeding the RMB32.68 million reported for the entirety of 2025. The company has set an ambitious annual sales target of over RMB150 million for 2026, reflecting management’s confidence in sustained momentum.

The company’s domestic B2C e-commerce performance is particularly noteworthy, with a 2,400% (25x) increase in sales year-on-year for Q1. The launch of the in-house live-streaming sales operation five months ago has been a key driver, with average daily sales approaching RMB100,000 and a recent single-day GMV of RMB400,000—a record for the company. This channel is rapidly proving its effectiveness in driving consumer engagement and sales velocity.

The overseas B2C e-commerce business also recorded a substantial 150% year-on-year growth in Q1, indicating strong international demand and successful execution against cross-border e-commerce strategies.

The B2B raw material sales segment has contributed RMB3.44 million in Q1 2026, compared to no revenue in the prior year’s first quarter, and already exceeds the full-year 2025 figure. This demonstrates the success of the company’s efforts to diversify revenue streams beyond finished goods into raw material supply.

Management has stated that cash flow from these fast-growing segments will be strategically deployed to fund the research, development, and commercialization of Kintor’s core pharmaceutical assets—KX-826 and GT20029—as well as other key pipeline projects. This reinvestment signals a disciplined approach to capital allocation and a focus on pipeline advancement, both of which are critical to the company’s long-term growth and valuation.

Shareholders and potential investors should note: The company’s rapid sales growth, successful expansion into new business models (particularly live-streaming and B2B sales), and clear commitment to pipeline development could all be significant share price catalysts. However, stakeholders are also advised to exercise caution when dealing in the shares, as the company’s future performance remains subject to market conditions and execution risks.

Board and Management

• Chairman, Executive Director, and CEO: Dr. Youzhi Tong
• Executive Director: Dr. Xiang Ni
• Non-executive Directors: Mr. Yunfei Chen, Ms. Geqi Wei
• Independent Non-executive Directors: Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung, Prof. Liang Tong

Disclaimer: This article is a summary and analysis based on Kintor Pharmaceutical Limited’s voluntary announcement. It contains forward-looking statements that involve risks and uncertainties. Investors should exercise caution and consult their financial advisors before making any investment decisions. The company’s actual results may differ from those projected or implied.

View KINTOR PHARMA-B Historical chart here